Short Interest in Applied DNA Sciences, Inc. (NASDAQ:APDN) Increases By 10.3%

Applied DNA Sciences, Inc. (NASDAQ:APDN) was the target of a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 298,700 shares, an increase of 10.3% from the March 31st total of 270,800 shares. Based on an average daily trading volume, of 150,500 shares, the days-to-cover ratio is currently 2.0 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Applied DNA Sciences stock. Silverberg Bernstein Capital Management LLC bought a new position in Applied DNA Sciences, Inc. (NASDAQ:APDN) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 98,301 shares of the technology company’s stock, valued at approximately $61,000. Silverberg Bernstein Capital Management LLC owned approximately 0.72% of Applied DNA Sciences at the end of the most recent quarter. Hedge funds and other institutional investors own 22.22% of the company’s stock.

Applied DNA Sciences Stock Down 11.9 %

APDN stock opened at $3.85 on Tuesday. Applied DNA Sciences has a 52-week low of $3.70 and a 52-week high of $37.20. The stock’s 50 day moving average is $8.98 and its two-hundred day moving average is $12.75. The company has a market capitalization of $3.27 million, a PE ratio of -0.36 and a beta of 0.07.

Applied DNA Sciences (NASDAQ:APDN) last posted its quarterly earnings data on Thursday, February 8th. The technology company reported ($1.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.20) by $4.40. Applied DNA Sciences had a negative return on equity of 159.93% and a negative net margin of 80.14%. The company had revenue of $0.89 million for the quarter, compared to the consensus estimate of $0.70 million. As a group, sell-side analysts anticipate that Applied DNA Sciences will post -12.6 EPS for the current year.

Analysts Set New Price Targets

APDN has been the topic of several analyst reports. StockNews.com initiated coverage on Applied DNA Sciences in a report on Monday. They set a “hold” rating on the stock. HC Wainwright dropped their price objective on Applied DNA Sciences from $40.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, February 9th.

Applied DNA Sciences Company Profile

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.